Longeveron to Present at Emerging Growth Virtual Conference on June 12, 2024

13 June 2024
Longeveron Inc., a biotechnology firm trading under NASDAQ: LGVN, announced its participation in the Emerging Growth Virtual Conference scheduled for June 12-13, 2024. The company's presentation is set for Wednesday, June 12, at 1:45 p.m. ET. Interested individuals can access the webcast via the “Events and Presentations” section on Longeveron's website. Following the conference, a replay of the webcast will be available online for 180 days. Attendees can submit questions ahead of time to Questions@EmergingGrowth.com or ask them during the event.

Longeveron Inc. specializes in developing regenerative medical treatments to meet unmet medical needs. Their leading investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ is believed to have several possible mechanisms of action, including promoting vascular health, regeneration, anti-inflammation, and tissue repair. These features grant it broad potential applications across various disease areas.

Currently, Longeveron is advancing research in three primary areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For additional information, individuals are encouraged to visit Longeveron's website or follow their updates on LinkedIn, X, and Instagram.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!